A new study recently held that most patients with mild Covid-19 infections produce antibodies that persist and protect them from re-infection for up to six months.
The University of Michigan research, published in the journal Microbiology Spectrum, included nearly 130 people with Covid-19 —Three of whom were hospitalized, while the rest were outpatients who experienced a mild infection—, those who underwent studies three and six months after initial infection.
Charles Schuler, lead author and assistant professor of allergy and immunology at Michigan Medicine, indicated that there was much concern that only those with severe Covid-19 would produce strong antibody responses to infection. But during follow-up they found that all but one had persistent antibody levels.
“We are showing that people with mild episodes did very well after infection, they produced antibodies and kept them.”, said.
Schuler’s team also found that the ability of the antibodies to neutralize the coronavirus at six months did not differ significantly from the first check-up, which occurred three months after infection.
“While some studies have suggested that Covid-19 antibodies decline over time, these findings provide strong prospective evidence for longer-term immunity for those who produce an immune response from a mild infection “said James Baker Jr., MD, author and founding director of the Mary H. Weiser Food Allergy Center at Michigan Medicine.
Currently, the team you are testing samples from this group taken up to one year after infection to further assess antibody responses. Meanwhile, they concluded that people who had Covid-19 can delay vaccination for up to 90 days after discharge from the disease.